Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05092477 · ClinicalTrials.gov registry record · NA
Integrated Intervention for Breast Cancer Survivors With Diabetes
A NA study, sponsored by Icahn School of Medicine at Mount Sinai.
- Completed
- Registry status
- NA
- Development phase
- 59
- Enrollment target
NCT05092477 is a NA study that has completed, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 59 participants.
The verdict
NCT05092477, a NA study, has completed, sponsored by Icahn School of Medicine at Mount Sinai.
- COMPLETED
- Registry status
- NA
- Development phase
- 59 participants
- Enrollment target
Study Summary
The purpose of this research study is to learn how therapy for breast cancer or DCIS/LCIS affects cognitive function and beliefs about cancer/DCIS/LCIS and diabetes (DM). For this portion of the study, the study team will integrate the information collected at previous follow-ups to create educational modules to change disease and medication beliefs and improve DM self-management behaviors (SMB). The educational counseling modules the study team plans to pilot test are rooted in the Common Sense Self-Regulation Model, a theory that posits that health behaviors are influenced by two parallel processes: cognitive (i.e., disease beliefs and expectations) and affective (i.e., emotional responses).
Interventions
- BEHAVIORAL Attention Control
- BEHAVIORAL Integrated Intervention for Breast Cancer Survivors with Diabetes
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 59 participants |
| Start Date | 2022-01-27 |
| Est. Completion | 2023-07-24 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05092477
The ClinicalTrials.gov registry entry for NCT05092477 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 59 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Icahn School of Medicine at Mount Sinai, which has 708 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Attention Control is the first listed.
NCT05092477 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05092477 about?
NCT05092477 is a clinical study titled "Integrated Intervention for Breast Cancer Survivors With Diabetes". The purpose of this research study is to learn how therapy for breast cancer or DCIS/LCIS affects cognitive function and beliefs about cancer/DCIS/LCIS and diabetes (DM). For this portion of the study, the study team will integrate the information collected at previous follow-ups to create education...
What is the current status of trial NCT05092477?
This trial is currently completed. It is a NA study. The enrollment target is 59 participants. The study started on 2022-01-27. Estimated completion is 2023-07-24.
What interventions are being tested in trial NCT05092477?
The interventions under investigation include: Attention Control (BEHAVIORAL), Integrated Intervention for Breast Cancer Survivors with Diabetes (BEHAVIORAL).
Who is sponsoring clinical trial NCT05092477?
This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.